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Abstract 
Tuberculosis (TB) has been the most common opportunistic infection and cause of mortality among HIV-infected 
patients, especially in resource-limited countries. Clinical manifestations of TB vary and depend on the degree of 
immunodeficiency. Sputum microscopy and culture with drug-susceptibility testing are recommended as a standard 
method for diagnosing active TB. TB-related mortality in HIV-infected patients is high especially during the first few 
months of treatment. Integrated therapy of both HIV and TB is feasible and efficient to control the diseases and yield 
better survival. Randomized clinical trials have shown that early initiation of antiretroviral therapy (ART) improves 
survival of HIV-infected patients with TB. A delay in initiating ART is common among patients referred from TB to HIV 
separate clinics and this delay may be associated with increased mortality risk. Integration of care for both HIV and TB 
using a single facility and a single healthcare provider to deliver care for both diseases is a successful model. For TB 
treatment, HIV-infected patients should receive at least the same regimens and duration of TB treatment as HIV-unin-
fected patients. Currently, a 2-month initial intensive phase of isoniazid, rifampin, pyrazinamide, and ethambutol, fol-
lowed by 4 months of continuation phase of isoniazid and rifampin is considered as the standard treatment of drug-
susceptible TB. ART should be initiated in all HIV-infected patients with TB, irrespective of CD4 cell count. The optimal 
timing to initiate ART is within the first 8 weeks of starting antituberculous treatment and within the first 2 weeks for 
patients who have CD4 cell counts <50 cells/mm3. Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART 
remains a first-line regimen for HIV-infected patients with TB in resource-limited settings. Although a standard dose of 
both efavirenz and nevirapine can be used, efavirenz is preferred because of more favorable treatment outcomes. In 
the settings where raltegravir is accessible, doubling the dose to 800 mg twice daily is recommended. Adverse reac-
tions to either antituberculous or antiretroviral drugs, as well as immune reconstitution inflammatory syndrome, are 
common in patients receiving integrated therapy. Early recognition and appropriate management of these conse-
quences can reinforce the successful integrated therapy in HIV-infected patients with TB.
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Background
Tuberculosis (TB) is one of the most common opportun-
istic infections among HIV-infected patients especially 
in resource-limited countries worldwide. In Africa and 
Asia, TB is also the most common cause of mortality in 
HIV-infected population [1]. HIV changes the clinical 
presentation of TB from a slowly progressing disease to 
one with a high mortality rate. A prospective multicenter 
cohort has clearly demonstrated that the risk of TB is 
associated with increasing immunodeficiency and TB 
occurrence significantly increases the risk of mortality 
[2]. Optimal treatment of TB with good patient compli-
ance can lead to the successful treatment and reduction 
of mortality [3].
Antiretroviral therapy (ART) has proven to have a great 
impact on survival rates among HIV-infected patients 
with TB [2, 4, 5]. Simultaneous treatment of both TB 
and HIV is required for HIV-infected patients present-
ing with TB. In addition, patients in resource-limited set-
tings with low CD4 cell counts, continue to present late 
to healthcare providers. New episodes of opportunistic 
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infections may develop within the first few months after 
ART and TB presents most frequently in this situation 
[6, 7]. An integrated therapy of both HIV and TB based 
on the current evidence of studies from both diseases 
has shown to be feasible and efficient in controlling the 
diseases and yields better survival in various clinical set-
tings. This article focuses on the integrated therapy for 
HIV-infected patients with active TB and details regard-
ing diagnosis and treatment of TB, initiation of ART, 
management of drug–drug interaction, overlapping tox-
icities of antituberculous and antiretroviral drugs, as well 
as TB immune reconstitution inflammatory syndrome 
are discussed.
Clinical manifestations of TB in HIV‑infected patients
TB among HIV-infected patients is resulted from reacti-
vation of past infection or new infection of Mycobacte-
rium tuberculosis [8]. Clinical manifestations are varying 
from classic symptoms of prolonged fever, hemoptysis, 
productive cough, weight loss, or night sweat to mini-
mal or nonspecific symptoms [9]. A previous study in 
Southeast Asia had reported that the presence of cough 
of any duration, fever of any duration, or night sweats 
lasting 3 or more weeks in the preceding 4  weeks was 
93 % sensitive and 36 % specific for tuberculosis [10]. The 
clinical features of TB depend on the degree of immuno-
deficiency. The presentation of pulmonary TB in AIDS 
patients may be atypical and unusual [11]. TB patients 
with CD4 cell counts less than 200 cells/mm3 are likely 
to have hilar or mediastinal adenopathy on chest radio-
graphs, but less likely to have cavitary lesion [12]. Miliary 
infiltrate is commonly found on chest radiographs among 
AIDS patients [13]. Normal radiographs can be found in 
14–22 % of HIV-associated TB [14, 15].
Extrapulmonary TB is common in HIV-infected 
patients and can be seen in up to 60 % of HIV-infected 
patients with TB [16, 17]. Patients with lower CD4 cell 
counts have the higher risk of extrapulmonary TB and 
mycobacteremia [18]. The frequent forms of extrapul-
monary disease are lymphadenitis, disseminated or 
bloodstream infection, and TB pleuritis [17–19]. TB 
meningitis is the most severe form of TB. High mortality 
rate is observed in spite of ART [20]. Other extrapulmo-
nary sites of HIV-associated TB include bone and joint, 
skin and soft tissue, pericardium, liver, spleen, kidney, 
gastrointestinal, and genitourinary tract [21].
Diagnosis of TB in HIV‑infected patients
A definitive diagnosis of TB is confirmed by culturing M. 
tuberculosis organisms from a specimen obtained from 
the patient. For pulmonary TB, sputum-smear for Ziehl-
Neelsen staining is fast, inexpensive, and a highly specific 
method. However, the sensitivity of direct microscopy 
in searching for acid-fast bacilli is variable from 31 to 
80  % according to a previous review [22]. Studies from 
Africa found that patients with concurrent HIV and TB 
infection have a higher frequency of smear-negative TB 
than those of HIV-uninfected patients [23]. Concentrat-
ing the specimen provided an additional positive yield 
of 36 % for the sputum-negative patients in a high HIV-
prevalent area [24]. Currently, sputum microscopy and 
culture in liquid medium with subsequent drug-suscep-
tibility testing are recommended as standard method for 
diagnosing active TB [25]. Nevertheless, the use of solid 
culture medium may be more cost-effective in resource-
limited countries. In systematic review, the mean time to 
detection with Löwenstein-Jensen cultures was 24  days, 
whereas automated mycobacterial liquid culture systems 
had a mean time to detection of 15 days [26]. Drug resist-
ant TB substantially reduces survival in HIV-infected 
patients with TB [27, 28]. Early detection and optimal 
treatment of drug resistant TB are crucial. Susceptibility 
testing of M. tuberculosis should be performed wherever 
this test is available.
Beyond sputum microscopy, new molecular diagnos-
tic tests provide a rapid diagnosis of active TB. Xpert 
MTB/RIF, the automated real-time nucleic acid amplifi-
cation assay, is endorsed for the diagnosis of pulmonary 
TB by World Health Organization [29]. Overall pooled 
sensitivity is 88 % and a pooled specificity is 99 % when 
used as an initial diagnostic test replacing smear micros-
copy. However, the pooled sensitivity of Xpert MTB/RIF 
decreases to 79  % for HIV-infected patients [29]. Other 
molecular tests, including MTBDRplus and LightCycler 
Mycobacterium Detection have demonstrated specifici-
ties of more than 97  %, but the sensitivities reduced by 
6 % when comparing with Xpert MTB/RIF test in HIV-
infected patients with pulmonary TB [30]. A tubercu-
lin skin test and an interferon-gamma release assay are 
unable to distinguish latent TB from active disease [8]. 
Usefulness of lipoarabinomannan (LAM) antigen-detec-
tion assay for the diagnosis of active TB in HIV-infected 
patients has recently been found to decrease mortality 
[31–33]. The implementation of LAM testing is likely to 
offer the greatest benefit in healthcare facilities where 
diagnostic resources are scarce and patients present with 
severe illness, advanced immunosuppression, and an ina-
bility to self-expectorate sputum [33].
For extrapulmonary disease, Ziehl-Neelsen stain helps 
to detect acid-fast bacilli in tissues and smears. However, 
the conventional smear microscopy has limited diag-
nostic value with low sensitivity [34, 35]. A recent meta-
analysis reported that Xpert MTB/RIF has an overall 
sensitivity of 83.1 % and a pooled specificity of 98.7 % for 
the diagnosis of extrapulmonary TB [36]. Xpert MTB/RIF 
is a sensitive diagnostic test for TB detection in lymph 
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node samples (83.1 %) and for the detection of TB men-
ingitis (80.5 %) while only 46.4 % pooled sensitivity was 
shown in testing with pleural fluid [36]. In tissue sam-
ples other than a lymph node, a pooled estimate of sen-
sitivity and specificity were 81.2 and 98.1 %, respectively 
[37]. However, direct methods sometimes fail to detect 
mycobacterium in the clinical specimens. Indirect meth-
ods sometimes help with diagnosis of extrapulmonary 
TB. In endemic TB areas, presence of granulomatous 
inflammation with or without caseation on histopathol-
ogy is suggestive for TB [38]. Another indirect test such 
as adenosine deaminase (ADA) test has considerable evi-
dence to support its use for diagnosis of pleural TB and 
to a slightly lesser extent for TB meningitis [39].
Integrated therapy of HIV and TB: general concept
Integrated therapy is crucial for HIV-infected patients 
with TB. The two diseases, HIV and TB, must be man-
aged simultaneously. TB-related mortality in HIV-
infected patients is high during the first few months of 
TB treatment [1]. Additionally, evidence from rand-
omized clinical trials and systemic review has shown that 
early initiation of ART improves survival of HIV-infected 
patients with TB [20, 40–46]. Managing the two diseases 
more effectively during this critical period is therefore 
essential to improve the patients’ survival and quality 
of life. The World Health Organization guidelines have 
recommended ART initiation during this time period 
[47–49]. However, ART initiation is often delayed due 
to various factors such as patient characteristics, over-
lapping drug toxicities, fear of clinicians or patients, and 
policies of local HIV and TB programs. Delay in initiat-
ing ART is more common among patients referred from 
TB to HIV separate clinics [50]. Delays in the initiation 
of ART in HIV-infected patients with TB, particularly 
those with very low CD4 cell counts, are associated with 
increased mortality risk.
The successful models of integration of care for both 
HIV and TB mainly use a single facility such as an inte-
grated HIV/TB care center and a single health care 
provider delivering care for both diseases [51, 52]. The 
advantages include providing faster initiation of ART 
treatment for HIV-infected patients with TB, holistic 
evaluation of the patients, and practical management 
when patients encounter adverse drug effects. In addi-
tion, this model in resource-limited settings is also more 
feasible to set up, maintain, and train the healthcare pro-
viders. A systematic review has demonstrated that inte-
grated care of HIV and TB may overcome challenges 
such as losing patients to follow-up during the referral 
process between TB and HIV clinics, burdening patients 
with increased travel costs and additional time spent in 
clinics [53]. Interventions for improving adherence and 
social support can also better reinforce this approach. 
Integrated therapy for both HIV and TB by the same 
team of healthcare providers may provide better clinical 
outcomes and use limited resource more efficiently.
Combination therapy of TB in general population
Streptomycin became the first effective treatment of TB 
in 1946, but the treatment was eventually a failure with 
frequent emergence of streptomycin resistance. The 
strategy to overcome the resistance problem with combi-
nation therapy of streptomycin, aminosalicylic acid, and 
isoniazid was reported in the 1950s. However, the treat-
ment period was not less than 1 year [54, 55]. After the 
discovery of rifampin and pyrazinamide, studies showed 
that the duration of treatment could be shortened to only 
6  months by the inclusion of rifampicin and pyrazina-
mide in the regimen [56, 57]. Currently, a 2-month initial 
intensive phase with isoniazid, rifampin, and pyrazina-
mide, followed by 4 months of a continuation phase with 
isoniazid and rifampin is considered as the standard 
treatment of drug-susceptible TB [58–60]. Ethambutol is 
usually recommended as the fourth drug in the intensive 
phase to prevent unrecognized resistance to one of the 
three core drugs [61]. Recent clinical trials in shortening 
TB treatment duration to 4 months by moxifloxacin- or 
gatifloxacin-containing regimens demonstrated a higher 
relapse rate than those of standard regimen [62–64].
The multidrug initial intensive phase is to reduce the 
bacillary load by killing mycobacteria rapidly and to pre-
vent the emergence of drug resistance. The continuation 
phase of therapy is given to kill the slowly replicating or 
non-replicating subpopulation. Isoniazid provides bac-
tericidal activity by initially killing about 95  % of bacilli 
during the first 2  days of treatment. Its bactericidal 
role is then replaced by rifampicin and pyrazinamide. 
Rifampicin and pyrazinamide are also responsible for the 
sterilizing activity by killing persistent or non-replicating 
organisms [55, 65]. A combination of at least two fully 
effective drugs was necessary to prevent the emergence 
of resistance [54].
Pulmonary and extrapulmonary TB should be treated 
with the same regimens [58]. Six months of standard 
therapy is generally considered adequate for most forms 
of extrapulmonary tuberculosis. However, treatment 
duration may need to be extended for central nervous 
system and skeletal tuberculosis. Although the optimal 
duration of therapy cannot be defined, the 9–12 months 
duration is recommended for the treatment of TB men-
ingitis because of serious risk of disability and mortality 
and for the treatment of TB of bone and joints because of 
the difficulties of assessing treatment response [58–60]. 
Adjunctive corticosteroids reduce the risk of death or 
disabling residual neurological deficit in patients with 
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tuberculous meningitis [66], and may be beneficial in 
those with tuberculous pericarditis [67]. An intensified 
regimen for TB meningitis that includes both a higher 
dose of oral rifampicin and the addition of levofloxacin to 
the standard regimen does not provide benefit on reduc-
ing overall mortality [68].
Treatment of TB in HIV‑infected patients
The principles for treatment of active TB disease in 
HIV-infected patients are the same as those for HIV-
uninfected patients. TB treatment is the priority. The 
regimens should include rifampicin and isoniazid [69, 
70]. The 6-month duration with standard regimen among 
HIV-infected patients showed similar cure and treat-
ment failure rates as in HIV-uninfected patients [71–73]. 
However, a meta-analysis on treatment of active TB in 
HIV-infected patients suggested that longer duration 
of rifamycin therapy (at least 8  months) were associ-
ated with a lower risk of TB relapse [74]. Intermittent 
intensive-phase treatment was associated with increased 
odds of treatment failure [75]. ART was found to lower 
the risk of TB relapse [74]. Studies to assess duration of 
rifamycin-based TB treatment and dosing schedule in 
patients receiving ART are needed for further evaluation. 
Currently, the World Health Organization’s guideline 
for the treatment of TB recommends that HIV-infected 
patients should, as a minimum, receive the same dura-
tion and daily dosing of TB treatment as HIV-uninfected 
patients. ART should be initiated in all HIV-infected with 
TB patients, irrespective of CD4 cell count [58].
Rifabutin induces CYP3A activity at a lesser magnitude 
than rifampicin and it may therefore be a more appropri-
ate option for co-administration with many antiretroviral 
drugs, including PIs [76]. Of noted, PIs increase the dose 
of rifabutin. Thus, rifabutin dosage required adjustment 
to minimize rifabutin-associated toxicity, including neu-
tropenia, uveitis, and liver toxicity [59]. A concern with 
rifabutin 150  mg thrice weekly is that rifabutin under 
exposure may result in acquired rifamycin resistance. 
Some experts recommend rifabutin at a dose of 150 mg 
daily when co-administered with any ritonavir-boosted 
PI [60, 61]. A recent randomized pharmacokinetic evalu-
ation of different rifabutin doses in African HIV- infected 
patients with TB and on lopinavir/ritonavir-based ART 
has demonstrated that a daily 150  mg dose of rifabutin 
in combination with lopinavir/ritonavir safely main-
tained rifabutin plasma concentrations [77]. To date, the 
replacement of rifampicin by rifabutin for first-line treat-
ment of TB is not supported by the current evidence [78].
ART in HIV‑infected patients with TB
The optimal timing to commence ART in HIV-infected 
patients with TB is relatively complex. It must balance 
the risk of morbidity and mortality in very advanced HIV 
disease with the potential occurrence of additive toxici-
ties, drug–drug interactions, and TB-associated immune 
reconstitution inflammatory syndrome (IRIS). The cur-
rent World Health Organization guidelines recommend 
that ART should be started as soon as possible “within 
the first 8  weeks” of starting antituberculous treatment 
and within the first 2 weeks for patients who have CD4 
cell counts less than 50 cells/mm3 [47–49]. The results 
from randomized control trials have been published over 
the past 5 years [40–44]. They have shown the same trend 
of survival benefit of concurrent ART during TB treat-
ment. In addition, ART initiation within the first 2 weeks 
of TB treatment is beneficial in patients with advanced 
HIV disease, i.e., CD4 cell count <50 cells/mm3 [40–44], 
although it is associated with a twofold higher frequency 
of TB IRIS [45]. TB IRIS is generally manageable and sur-
vival benefits of early ART in this group outweigh the risk 
of TB IRIS.
In patients with CD4 cell counts higher than 50 cells/
mm3, evidence is insufficient to support or refute a sur-
vival benefit conferred by early ART initiation [45]. 
Recently, a randomized control study in co-infected HIV 
and TB patients with high CD4 cell counts showed no 
difference of mortality between early and deferred ART 
on the unfavorable composite endpoint of death, tuber-
culosis treatment failure, and recurrence [46]. There-
fore, patients with less immune deficiency, i.e., CD4 cell 
counts higher than 50 cells/mm3, ART may be deferred 
until completion of intensive phase of TB treatment 
without compromising survival. In addition, a study in 
HIV-associated TB meningitis showed that immediate 
ART was not associated with reduced 9-month mortal-
ity, when compared to deferred ART initiation [20]. The 
adverse events were significantly more frequently found 
in both overall and during the first 2 months of treatment 
in immediate versus deferred ART arm [20]. Nonethe-
less, treatment guidelines in the resource-rich setting 
recommends to start ART as soon as possible with close 
monitoring and prompt management of adverse reac-
tions and central nervous system IRIS [69]. Thus, caution 
in early ART initiation is warranted in patients with TB 
meningitis. Table  1 summarizes all randomized control 
trials of the timing to initiate ART during TB treatment.
A rifamycin-containing antituberculous regimen is cru-
cial in the treatment of drug-sensitive TB. The regimens 
which do not contain rifampicin during the continuation 
phase are significantly inferior to the standard 6-month 
regimen in newly diagnosed smear-positive pulmonary 
TB [79]. Rifapentine, a long-acting rifamycin, is not rec-
ommended for TB treatment in HIV-infected patients 
receiving ART because of significant cytochrome P 450 
induction. Both rifampin and rifabutin are less strong 
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hepatic cytochrome P 450 inducers. However, these two 
drugs upregulate the uridine diphosphate glucuronosyl-
transferase 1A1 enzymes [80]. Therefore, they are associ-
ated with significant drug–drug interactions in different 
magnitudes with many antiretroviral drugs, including all 
protease inhibitors (PIs), non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs), and integrase inhibitors. 
Despite the problem of drug–drug interactions between 
rifamycins and antiretroviral drugs, simultaneous treat-
ment of both TB and HIV are required. Co-administra-
tion of rifampin and PIs is not recommended owing to 
significantly decreased plasma concentrations of all PIs 
and poor treatment outcomes [81–83]. Increasing the 
dosage of ritonavir or other PIs has resulted in unaccep-
table rates of liver toxicity and intolerability [84, 85]. A 
small study of double-dose lopinavir–ritonavir in combi-
nation with rifampicin-based antituberculosis treatment 
in South Africa has shown the favourable outcomes, with 
80  % of patients achieving TB treatment success. How-
ever, 36 % of patients experienced gastrointestinal toxic-
ity and 12 % had elevated liver enzymes [86].
In many resource-limited settings where HIV and TB 
are epidemic, NNRTI-based ART remains a first-line 
regimen. Previous studies have shown some effects of 
rifampicin on the minimal efavirenz concentrations. 
Some experts recommend increasing the dosage of efa-
virenz from 600 to 800  mg/day in patients with body 
weight more than 50  kg to overcome the drug–drug 
interactions [87]. Subsequent trials have shown that 
concomitant use of standard-dose efavirenz at 600  mg/
day and rifampicin does not compromise the clinical 
treatment outcomes [88–92]. However, certain genetic 
polymorphisms of efavirenz metabolism, i.e., single 
nucleotide polymorphisms of the hepatic cytochrome 
P450 isoenzyme 2B6 (CYP2B6) gene, have been associ-
ated with high inter-patient variations in its plasma con-
centrations. The CYP 2B6 516G>T is associated with 
high plasma concentrations even among patients con-
currently receiving rifampicin [93–96]. Given its proven 
efficacy and simplicity, the use of a standard dose of efa-
virenz at 600  mg/day combined with two NRTIs is the 
recommended regimen in antiretroviral-naïve patients 
who are receiving rifampicin.
Prior studies demonstrated that rifampicin reduces 
plasma concentrations of nevirapine by 20–55 % [97–99]. 
However, virological and immunological responses to 
nevirapine-based ART when given at a dose of 200  mg 
twice daily were similar for patients that are and are not 
receiving rifampin-containing antituberculous treatment 
[100]. Additionally, a 2-week lead-in period of nevirap-
ine is associated with a higher chance of virological fail-
ure owing to subtherapeutic concentration of nevirapine 
[91]. Non-inferiority of the nevirapine-based ART was 
not shown in a head-to-head comparison with efavirenz-
based ART. With regards to safety, nevirapine at full dose 
could be a safe, acceptable alternative for patients unable 
to tolerate efavirenz and other options are not available 
[101]. A higher dose of nevirapine at 300 mg twice daily 
to overcome drug–drug interactions is associated with 
higher rates of liver toxicity [102]. Rifampicin signifi-
cantly reduces plasma concentrations of rilpivirine and 
etravirine, thus, these drugs are not recommended to 
be co-administered with rifampicin [103]. With regards 
to integrase inhibitor, raltegravir co-administered with 
rifampicin resulted in lower raltegravir minimum con-
centration by 61  %. Doubling the dose of raltegravir to 
800 mg when co-administered with rifampicin can com-
pensate the effect of rifampicin on raltegravir area under 
the curve but not overcome the effect on concentration 
at 12 h after dosing [104].
In the phase II study, high rates of success were 
achieved at 48 weeks with raltegravir 400 mg twice daily, 
800 mg twice daily, or efavirenz 600 mg once daily when 
used in combination with tenofovir and lamivudine in 
patients receiving a rifampin-containing TB treatment 
[105]. However, further larger and long-term studies 
remain needed to confirm this finding. Given rifampicin 
lowers the minimum concentration of raltegravir, dou-
bling the dose of raltegravir to 800 mg twice daily should 
be an appropriate treatment strategy. Studies examining 
the concomitant use of dolutegravir and rifampicin are 
ongoing.
The rapid worldwide scale‐up of ART in the resource-
limited settings has led to increasing numbers of patients 
failing first‐line ART. The options for second-line ART 
after failure with a first-line NNRTI-based regimen gen-
erally involve the switch to a PI combined with an alter-
nate NRTI backbone. As aforementioned, the drug–drug 
interactions between rifampicin and PIs are extensive. 
Therefore, rifabutin should be an appropriate alternative 
rifamycin in this setting although clinical data regard-
ing safety and efficacy in the treatment of TB in HIV-
infected patients is scanty. However, rifabutin is not 
available in many countries and it is not produced in 
fixed dose combination. Thus, an alternative option is 
using a non-rifamycin anti-TB regimen in HIV-infected 
patients receiving PIs. Fluoroquinolones such as ofloxa-
cin, levofloxacin, or ciprofloxacin may be used to sub-
stitute rifampicin. In addition, a non-rifamycin anti-TB 
regimen should be given for a period of 9–12  months. 
The management of HIV-infected patients taking PIs and 
undergoing treatment for active TB with a non-rifamycin 
anti-TB regimen should be directed by, or conducted 
in consultation with, a physician with experience in the 
care of patients with these two diseases. This care should 
include close attention to the possibility of TB treatment 
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failure, antiretroviral treatment failure, and overlapping 
toxicities for all drugs used.
Overlapping toxicities of antituberculous and antiretroviral 
drugs
Adverse drug reactions occur more frequently among 
HIV-infected patients with TB who are receiving con-
current treatment of HIV and TB than HIV-uninfected 
patients [106, 107]. The common overlapping toxicity 
profiles include liver toxicity, skin reactions, renal tox-
icity, and gastrointestinal reactions [108–113]. Table  2 
shows the common overlapping adverse events of first-
line antituberculous drugs and antiretroviral drugs. 
These reactions may be complicated and need intensive 
management in some patients. Early recognition of these 
adverse events and prompt appropriate management of 
these problems can lead to successful integrated therapy 
in HIV-infected patients with TB.
TB IRIS
TB IRIS may develop among HIV-infected patients who 
had recently diagnosed active TB or had undiagnosed 
TB and subsequently received effective ART. TB IRIS 
or TB-associated immune recovery disease refers to an 
inflammatory reaction directed to M. tuberculosis anti-
gen presenting at the sites of infection. Two patterns of 
TB IRIS have been described in the literatures, including 
paradoxical TB IRIS and unmasking TB IRIS. The para-
doxical TB-IRIS is defined as the deterioration of existing 
TB lesions after recent initiation, re-initiation or switch 
to more effective ART. The patients with paradoxical TB 
IRIS typically have clinical improvement or clinical sta-
bilization from receiving antituberculous treatment for 
a short period of time before initiating ART. The epide-
miologic data of paradoxical TB-IRIS are variable, rang-
ing from 8 to 42 % [114–118]. However, a meta-analysis 
showed that the frequency of paradoxical TB IRIS was 
15.7 %, with a mortality rate of 3.2 % [119]. The onset of 
paradoxical TB IRIS typically develops between 1 and 
4  weeks after ART commencement and the symptoms 
lasts for 2–3  months. However, late manifestations of 
IRIS may present. The common manifestations include 
high fever, worsening of lymph node enlargement (Fig. 1), 
and new or worsening of lung infiltration. The neurologi-
cal TB IRIS may present with cerebral abscess, menin-
gitis, and radiculomyelitis [120, 121]. The identified risk 
factors of paradoxical TB IRIS include low nadir CD4 cell 
count at ART initiation [117, 122], extrapulmonary or 
disseminated TB [116, 123] and a short period between 
starting TB treatment and ART [118]. The risk factors 
associated with death in paradoxical TB IRIS included a 
low nadir CD4 cell count prior to ART initiation and a 
shorter period between initiating antituberculous treat-
ment and ART [48, 77].
The second pattern, unmasking TB IRIS, occurs after 
ART initiation in HIV-infected patients with undiag-
nosed active TB. The subsequent immune restoration 
provokes the exaggerated symptoms of TB [124]. Thus, 
the risk factor of unmasking TB IRIS relates to the effi-
ciency of TB screening and diagnosis of subclinical TB 
prior to ART initiation. A typical clinical presentation 
is rapid onset and clinical features of TB at the site of 
infection, such as high fever, pneumonitis, and lym-
phadenitis [125, 126]. The symptoms may mimic bacte-
rial sepsis.
The consensus case definition of both patterns of TB 
IRIS is still debated because they do not provide clear 
consensus on diagnosis [127–129]. The proposed defi-
nition of diagnosis in the resource-limited settings has 
been published previously by the INSHI group [129]. 
However, patients with undiagnosed multidrug-resist-
ant TB may mimic the symptoms of paradoxical TB 
IRIS. Thus, antituberculous drug resistance should be 
excluded in all cases of suspected TB IRIS. In addition, 
inadequate or inappropriate TB treatment, other concur-
rent opportunistic infections, and adverse drug reactions 
need to be excluded. With regard to unmasking TB IRIS, 
some residual immune deficiency leading to a new TB 
and deterioration of subclinical TB disease may mimic 
unmasking TB IRIS [124].
Table 2 Common overlapping adverse events of first-line antituberculous drugs and antiretroviral drugs
Adverse events Antituberculous drugs Antiretroviral drugs Clinical characteristics
Skin reaction [108] Rifamycins, isoniazid, pyrazinamide,  
ethambutol, streptomycin
Nevirapine, efavirenz, abacavir Morbilliform rashes, Steven Johnson syn-
drome and toxic epidermal necrolysis, 
fixed drug eruption, lichenoid drug 
eruptions and acute generalized exan-
thematous pustulosis
Liver toxicity [109–112] Rifamycins, isoniazid, pyrazinamide Nevirapine, efavirenz, protease inhibi-
tors
Transaminitis, cholestatic hepatitis
Renal toxicity [113] Tenofovir Streptomycin, rifamycins Tubulo-interstitial nephritis, proximal 
tubulopathy, acute renal failure
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Three major factors involve the pathogenesis of TB-
IRIS, including (1) mycobacterial antigen burden and 
anti-TB treatment, (2) immune system function of the 
patients, and (3) ART initiation and potency. The role 
of mycobacterial antigen burden is suggested by the risk 
of TB IRIS that is greater in the patients with earlier 
ART initiation during TB treatment when the residual 
mycobacterial load remains high and in those with dis-
seminated TB [124, 130]. Mycobacterial antigen releas-
ing from the killing bacilli with TB treatment stimulates 
an exuberant inflammatory response. The host immune 
system also plays roles in the pathogenesis of TB IRIS. 
Pre-existing immune deficiency has been shown to pre-
dispose to TB IRIS. Many previous studies revealed that 
the low nadir CD4 cell counts have been related to sub-
sequent IRIS [119, 131, 132]. High plasma HIV viral load 
has been reported to be associated with TB IRIS [133]. 
In addition, it is associated with an exuberant produc-
tion of inflammatory cytokines, such as IFN-gamma 
[134, 135]. In terms of ART, not only the rate of CD4 cell 
count recovery in peripheral blood after ART initiation is 
associated with TB IRIS [115], but the ART may also trig-
ger local immune reconstitution via increased numbers 
of infiltrating MTB-specific CD4+ T cells at the site of 
infection [136].
Most cases of paradoxical TB IRIS are self-limited. 
When mild paradoxical TB IRIS occurs, symptomatic 
and supportive treatment can be given, including anal-
gesic drugs, anti-pyretic drugs, and anti-emetic drugs. 
Local drainage of abscess may be required in some cases. 
Nonsteroidal anti-inflammatory drugs can be used for 
those cases in which inflammation or fever cause patients 
discomfort. Moderate to severe TB IRIS may threaten 
the clinical status of patients, such as neurologic seque-
lae from TB of central nervous system and decreased 
pulmonary function of pulmonary TB IRIS. In such 
cases, anti-inflammatory treatment should be consid-
ered. A randomized control trial showed that predniso-
lone at 1.5 mg/kg/day for 2 weeks followed by 0.75 mg/
kg/day for an additional 2 weeks resulted in a reduction 
of hospitalization and therapeutic procedures [137]. In a 
case series diagnosed with severe TB IRIS, time to symp-
tom improvement with prednisolone 10–80 mg/day was 
3  days [118]. However, adverse effects of corticosteroid 
treatment should be monitored. ART interruption is not 
recommended because of increased risk of antiretroviral 
drug resistance and developing of opportunistic infec-
tions. Other potential drugs used to treat TB IRIS are 
thalidomide, leukotriene receptor antagonists, pentoxi-
fylline, and hydroxychloroquine [138].
Conclusions
Managing HIV and TB simultaneously is essential to 
improve patients’ survival and quality of life. Integration 
of care for both HIV and TB using a single facility and 
a single health care provider is a model to deliver inte-
grated therapy for both diseases and manage adverse 
drug effects efficiently. Based on the evidence from ran-
domized clinical trials and systemic review, various treat-
ment guidelines have recommended early ART initiation. 
Integrated therapy is crucial for HIV-infected patients 
with TB. For TB treatment, a 2-month initial intensive 
phase of isoniazid, rifampin, pyrazinamide, and etham-
butol, followed by 4  months of a continuation phase of 
isoniazid and rifampin is considered as the standard 
treatment of drug-susceptible TB. Rifabutin induces 
CYP3A activity at a lesser magnitude than rifampicin and 
it may be a more appropriate option for co-administra-
tion of many antiretroviral drugs, including PIs. How-
ever, rifabutin is not available in many resource-limited 
countries—where HIV and TB are epidemic.
ART should be initiated in all HIV-infected patients 
with TB, irrespective of CD4 cell count. The optimal 
timing to commence ART in HIV-infected patients with 
TB is within the first 8 weeks of starting antituberculous 
treatment and within the first 2  weeks for patients who 
Fig. 1 Paradoxical TB IRIS presenting as worsening of lymph node 
enlargement
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have CD4 cell counts less than 50 cells/mm3. In resource-
limited settings, NNRTI-based ART remains a first-line 
regimen. A standard dose of efavirenz at 600  mg/day 
combined with two NRTIs is the recommended regi-
men in antiretroviral-naïve patients who are receiving 
rifampicin. A standard dose of nevirapine without lead-
in could be a safe and acceptable alternative for patients 
unable to tolerate efavirenz. In the settings where ralte-
gravir is available and accessible, doubling the dose of 
raltegravir to 800  mg twice daily combined with two 
NRTIs is recommended. Adverse reactions to either 
antituberculous or antiretroviral drugs are common 
in patients receiving integrated therapy. TB IRIS may 
develop among HIV-infected patients who had recently 
been diagnosed with active TB, received TB treatment, 
and subsequently received effective ART. Early recogni-
tion and appropriate management of these problems can 
lead to successful integrated therapy in HIV-infected 
patients with TB.
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